These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
629 related articles for article (PubMed ID: 28212996)
1. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs). Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996 [TBL] [Abstract][Full Text] [Related]
2. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. Padda SK; Riess JW; Schwartz EJ; Tian L; Kohrt HE; Neal JW; West RB; Wakelee HA J Thorac Oncol; 2015 Mar; 10(3):500-8. PubMed ID: 25402569 [TBL] [Abstract][Full Text] [Related]
3. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188 [TBL] [Abstract][Full Text] [Related]
4. Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma. Wei YF; Chu CY; Chang CC; Lin SH; Su WC; Tseng YL; Lin CC; Yen YT Lung Cancer; 2018 Nov; 125():35-42. PubMed ID: 30429036 [TBL] [Abstract][Full Text] [Related]
5. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic and clinical significance of KIT(CD117) expression in thymic epithelial tumors in China. Song N; Chen G; Zhang P; Liu M; He WX; Jiang GN Asian Pac J Cancer Prev; 2012; 13(6):2745-8. PubMed ID: 22938452 [TBL] [Abstract][Full Text] [Related]
8. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603 [TBL] [Abstract][Full Text] [Related]
9. Tumor immunity is related to Imai H; Kaira K; Hashimoto K; Nitanda H; Taguchi R; Yanagihara A; Umesaki T; Yamaguchi O; Mouri A; Kawasaki T; Yasuda M; Kobayashi K; Sakaguchi H; Kuji I; Kagamu H Cancer Med; 2021 Sep; 10(18):6317-6326. PubMed ID: 34363337 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277 [TBL] [Abstract][Full Text] [Related]
11. PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature. Guleria P; Husain N; Shukla S; Kumar S; Parshad R; Jain D Ann Diagn Pathol; 2018 Jun; 34():135-141. PubMed ID: 29661720 [TBL] [Abstract][Full Text] [Related]
12. Absence of gene mutations in KIT-positive thymic epithelial tumors. Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988 [TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach. Berardi R; Goteri G; Brunelli A; Pagliaretta S; Paolucci V; Caramanti M; Rinaldi S; Refai M; Pompili C; Morgese F; Torniai M; Marcantognini G; Ricci G; Mazzanti P; Onofri A; Bianchi F; Sabbatini A; Cascinu S Expert Opin Ther Targets; 2020 Sep; 24(9):937-943. PubMed ID: 32662701 [TBL] [Abstract][Full Text] [Related]
14. Expression and mutational status of c-kit in thymic epithelial tumors. Petrini I; Zucali PA; Lee HS; Pineda MA; Meltzer PS; Walter-Rodriguez B; Roncalli M; Santoro A; Wang Y; Giaccone G J Thorac Oncol; 2010 Sep; 5(9):1447-53. PubMed ID: 20651610 [TBL] [Abstract][Full Text] [Related]
15. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Schirosi L; Nannini N; Nicoli D; Cavazza A; Valli R; Buti S; Garagnani L; Sartori G; Calabrese F; Marchetti A; Buttitta F; Felicioni L; Migaldi M; Rea F; Di Chiara F; Mengoli MC; Rossi G Ann Oncol; 2012 Sep; 23(9):2409-2414. PubMed ID: 22357254 [TBL] [Abstract][Full Text] [Related]
16. Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center. Okuma Y; Hosomi Y; Watanabe K; Yamada Y; Horio H; Maeda Y; Okamura T; Hishima T BMC Cancer; 2014 May; 14():349. PubMed ID: 24885581 [TBL] [Abstract][Full Text] [Related]
17. Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets. Enkner F; Pichlhöfer B; Zaharie AT; Krunic M; Holper TM; Janik S; Moser B; Schlangen K; Neudert B; Walter K; Migschitz B; Müllauer L Pathol Oncol Res; 2017 Jul; 23(3):551-564. PubMed ID: 27844328 [TBL] [Abstract][Full Text] [Related]
18. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Weissferdt A; Fujimoto J; Kalhor N; Rodriguez J; Bassett R; Wistuba II; Moran CA Mod Pathol; 2017 Jun; 30(6):826-833. PubMed ID: 28281549 [TBL] [Abstract][Full Text] [Related]
19. Impact of PD-L1, transforming growth factor-β expression and tumor-infiltrating CD8 Duan J; Liu X; Chen H; Sun Y; Liu Y; Bai H; Wang J Thorac Cancer; 2018 Nov; 9(11):1341-1353. PubMed ID: 30168897 [TBL] [Abstract][Full Text] [Related]